| Literature DB >> 26603157 |
Abstract
BACKGROUND: In the consideration of ampullary adenocarcinoma, T stage, lymph node metastases, perineural invasion, tumor differentiation, pancraticobiliary type, and lymph node ratio are considered prognostic factors. The objectives of this study were to investigate surgical outcomes and the clinicopathological predictors affecting survival and recurrence, and to examine the prognostic roles of histopathological subtype and immunohistochemical markers.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26603157 PMCID: PMC4657248 DOI: 10.1186/s12876-015-0396-x
Source DB: PubMed Journal: BMC Gastroenterol ISSN: 1471-230X Impact factor: 3.067
Fig. 1Cytokeratin 7 (CK7) and cytokeratin 20 (CK20) expression in ampulla of Vater adenocarcinoma. a, b CK7 and CK 20 in one patient displaying intestinal subtype adenocarcinoma. a CK7 negative and b CK20 positive. c, d one patient displaying pancreaticobiliary type adenocarcinoma. c CK7 positive and d CK20 negative
Demographics and clinical characteristics of patients with ampullary adenocarcinoma
| Variables | |
|---|---|
| Total number | 37 (100 %) |
| Sex | |
| Male | 18 (48.6 %) |
| Female | 19 (51.4 %) |
| Age, years | 62.57 ± 8.22 |
| T stage | |
| T1 | 14 (37.8 %) |
| T2 | 8 (21.6 %) |
| T3 | 14 (37.8 %) |
| T4 | 1 (2.7 %) |
| N stage | |
| N0 | 31 (83.8 %) |
| N1 | 6 (16.2 %) |
| Overall stage | |
| IA | 14 (37.8 %) |
| IB | 6 (16.2 %) |
| IIA | 11 (29.7 %) |
| IIB | 5 (13.5 %) |
| III | 1 (2.7 %) |
| Tumor size (cm) | 2.58 ± 1.49 |
| CA19-9 (U/ml) | 459.54 ± 1727.30 |
| CEA (ng/ml) | 4.03 ± 5.65 |
| Lymphovascular invasion | |
| No | 31 (83.8 %) |
| Yes | 6 (16.2 %) |
| Perineural invasion | |
| No | 30 (81.1 %) |
| Yes | 7 (18.9 %) |
| Differentiation | |
| Well/Moderately | 31 (83.8 %) |
| Poorly | 6 (16.2 %) |
| Adjuvant therapy | |
| No | 20 (54.0 %) |
| Yes | 17 (46.0 %) |
CA19-9 Carbohydrate antigen 19–9, CEA Carcinoembryonic antigen
Univariate analysis for predictive factors influencing overall survival and disease-free survival after curative resection
| Variables | N | 5 years survival rate | Overall survival | 5 years survival rate | Disease-free survival | ||
|---|---|---|---|---|---|---|---|
| Hazard ratio | Hazard ratio | ||||||
| Sex | |||||||
| Male | 18 | 87.2 | 2.33 (0.45–12.05) | 0.311 | 77.8 | 1.07 (0.28–3.99) | 0.919 |
| Female | 19 | 68.0 | 73.7 | ||||
| Age, years | |||||||
| < 60 | 14 | 80.0 | 1.79 (0.34–9.21) | 0.489 | 78.6 | 1.27 (0.32–5.09) | 0.733 |
| ≥ 60 | 23 | 75.9 | 73.9 | ||||
| Subtype | |||||||
| Intestinal | 17 | 93.3 | 8.45 (0.99–71.61) | 0.051 | 94.1 | 8.34 (1.04–66.88) | 0.046 |
| Pancreaticobiliary | 20 | 60.5 | 60.0 | ||||
| CK7 +/CK20 - | |||||||
| No | 19 | 93.3 | 9.74 (1.16–81.89) | 0.036 | 89.5 | 4.31 (0.89–20.77) | 0.069 |
| Yes | 18 | 57.5 | 61.1 | ||||
| CDX2 | |||||||
| No | 20 | 75.2 | 1.26 (0.28–5.68) | 0.764 | 75.0 | 1.02 (0.28–3.81) | 0.972 |
| Yes | 16 | 79.3 | 75.0 | ||||
| T stage | |||||||
| T1, T2 | 22 | 95.2 | 13.94 (1.66–117.03) | 0.015 | 95.5 | 14.81 (1.85–118.92) | 0.011 |
| T3, T4 | 15 | 45.4 | 46.7 | ||||
| Lymph node metastasis | |||||||
| No | 31 | 88.4 | 6.00 (1.30–27.58) | 0.021 | 83.9 | 5.69 (1.52–21.30) | 0.010 |
| Yes | 6 | 33.3 | 33.3 | ||||
| Lymphovascular invasion | |||||||
| No | 31 | 85.1 | 5.89 (1.27–27.38) | 0.024 | 83.9 | 6.06 (1.58–23.28) | 0.009 |
| Yes | 6 | 31.3 | 33.3 | ||||
| Perineural invasion | |||||||
| No | 30 | 84.0 | 4.83 (1.07–21.87) | 0.041 | 83.3 | 4.88 (1.29–18.40) | 0.019 |
| Yes | 7 | 47.6 | 42.9 | ||||
| Size | |||||||
| < 2 cm | 14 | 83.1 | 1.92 (0.37–9.94) | 0.436 | 85.7 | 2.34 (0.49–11.25) | 0.290 |
| ≥ 2 cm | 23 | 73.8 | 69.6 | ||||
| Differentiation | |||||||
| Well/mod | 31 | 86.0 | 8.18 (1.57–42.67) | 0.013 | 87.1 | 12.29 (3.06–48.31) | <0.001 |
| Poorly | 6 | 0 | 16.7 | ||||
| Stage | |||||||
| I and IIA | 31 | 88.4 | 6.00 (1.30–27.58) | 0.021 | 83.9 | 5.69 (1.52–21.30) | 0.010 |
| IIB and III | 6 | 33.3 | 33.3 | ||||
| Ca19-9 (U/ml) | |||||||
| < 37 | 12 | 70.0 | 0.66 (0.13–3.28) | 0.611 | 66.7 | 0.40 (0.09–1.81) | 0.236 |
| ≥ 37 | 20 | 84.0 | 85.0 | ||||
| CEA (ng/ml) | |||||||
| < 5 | 27 | 83.2 | 1.28 (0.14–11.54) | 0.826 | 81.5 | 1.37 (0.16–11.74) | 0.774 |
| ≥ 5 | 4 | 75.0 | 75.0 | ||||
| Pancreatic fistula | |||||||
| No | 21 | 77.2 | 0.88 (0.20–3.95) | 0.872 | 71.4 | 0.59 (0.15–2.35) | 0.453 |
| Yes | 16 | 77.9 | 81.3 | ||||
| Adjuvant therapy | |||||||
| No | 20 | 90.0 | 3.67 (0.70–19.02) | 0.122 | 90.0 | 5.11 (1.06–24.68) | 0.042 |
| Yes | 17 | 58.2 | 58.8 | ||||
CK7 Cytokeratin 7, CK20 Cytokeratin 20, CA19-9 Carbohydrate antigen 19–9, CEA Carcinoembryonic antigen
Fig. 2Overall survival in patients with resected ampulla of Vater adenocarcinoma according to immunohistochemical expression
Multivariate analysis of overall survival in patients with ampullary adenocarcinoma
| Variables | Hazard ratio | |
|---|---|---|
| CK7+/CK20- | ||
| No | Ref. | 0.046 |
| Yes | 8.96 (1.04–77.38) | |
| T stage | ||
| T1, T2 | Ref. | 0.019 |
| T3, T4 | 12.98 (1.52–110.78) | |
| Lymph node metastasis | ||
| No | Ref. | 0.276 |
| Yes | 2.45 (0.49–12.33) | |
| Lymphovascular invasion | ||
| No | Ref. | 0.678 |
| Yes | 0.67 (0.10–4.55) | |
| Differentiation | ||
| Well/mod | Ref. | 0.955 |
| poorly | 1.05 (0.17–6.59) | |
CK7 Cytokeratin 7, CK20 Cytokeratin 20
Multivariate analysis of disease-free survival in patients with ampullary adenocarcinoma
| Variables | Hazard ratio | |
|---|---|---|
| Subtype | ||
| Intestinal | Ref. | 0.664 |
| Pancreaticobiliary | 1.72 (0.15–19.54) | |
| T stage | ||
| T1, T2 | Ref. | 0.063 |
| T3, T4 | 8.21 (0.89–75.54) | |
| Lymph node metastasis | ||
| No | Ref. | 0.091 |
| Yes | 3.35 (0.82–13.63) | |
| Lymphovascular invasion | ||
| No | Ref. | 0.447 |
| Yes | 1.97 (0.34–11.39) | |
| Differentiation | ||
| Well/mod | Ref. | 0.031 |
| poorly | 4.95 (1.16–21.18) | |